Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study

Abstract

SummaryBackgroundAlthough a preventable and treatable disease, tuberculosis causes more than a million deaths each year. As countries work towards achieving the Sustainable Development Goal (SDG) target to end the tuberculosis epidemic by 2030, robust assessments of the levels and trends of the burden of tuberculosis are crucial to inform policy and programme decision making. We assessed the levels and trends in the fatal and non-fatal burden of tuberculosis by drug resistance and HIV status for 195 countries and territories from 1990 to 2016.MethodsWe analysed 15 943 site-years of vital registration data, 1710 site-years of verbal autopsy data, 764 site-years of sample-based vital registration data, and 361 site-years of mortality surveillance data to estimate mortality due to tuberculosis using the Cause of Death Ensemble model. We analysed all available data sources, including annual case notifications, prevalence surveys, population-based tuberculin surveys, and estimated tuberculosis cause-specific mortality to generate internally consistent estimates of incidence, prevalence, and mortality using DisMod-MR 2.1, a Bayesian meta-regression tool. We assessed how the burden of tuberculosis differed from the burden predicted by the Socio-demographic Index (SDI), a composite indicator of income per capita, average years of schooling, and total fertility rate.FindingsGlobally in 2016, among HIV-negative individuals, the number of incident cases of tuberculosis was 9·02 million (95% uncertainty interval [UI] 8·05–10·16) and the number of tuberculosis deaths was 1·21 million (1·16–1·27). Among HIV-positive individuals, the number of incident cases was 1·40 million (1·01–1·89) and the number of tuberculosis deaths was 0·24 million (0·16–0·31). Globally, among HIV-negative individuals the age-standardised incidence of tuberculosis decreased annually at a slower rate (–1·3% [–1·5 to −1·2]) than mortality did (–4·5% [–5·0 to −4·1]) from 2006 to 2016. Among HIV-positive individuals during the same period, the rate of change in annualised age-standardised incidence was −4·0% (–4·5 to −3·7) and mortality was −8·9% (–9·5 to −8·4). Several regions had higher rates of age-standardised incidence and mortality than expected on the basis of their SDI levels in 2016. For drug-susceptible tuberculosis, the highest observed-to-expected ratios were in southern sub-Saharan Africa (13·7 for incidence and 14·9 for mortality), and the lowest ratios were in high-income North America (0·4 for incidence) and Oceania (0·3 for mortality). For multidrug-resistant tuberculosis, eastern Europe had the highest observed-to-expected ratios (67·3 for incidence and 73·0 for mortality), and high-income North America had the lowest ratios (0·4 for incidence and 0·5 for mortality).InterpretationIf current trends in tuberculosis incidence continue, few countries are likely to meet the SDG target to end the tuberculosis epidemic by 2030. Progress needs to be accelerated by improving the quality of and access to tuberculosis diagnosis and care, by developi...

Aftermath of pulmonary tuberculosis: computed tomography assessment

“…Ninety patients (90%) presented with parenchymal fibrosis, architectural distortion ( Figure 1), and associated volume loss; with the commonest pattern of involvement being bilateral upper lobes (32/90 [35.56%]). The volume of lung involvement was objectively graded, and the mean score of parenchymal involvement was 9.3 ±4.4 (range, [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Bronchogenic carcinoma was not noted in any of our patients.…”

“…Pulmonary tuberculosis (PTB) contributes largely to the world health burden, not only due to the morbidity and mortality associated with active disease but also the morbidity associated with its sequelae [1][2][3]. Incidence of pulmonary tuberculosis is on the rise, with associated under-nutrition, diabetes, increasing prevalence of immunosuppression associated with AIDS, immunosuppressant drugs used with cancer chemotherapy or transplants, etc.…”

“…Incidence of pulmonary tuberculosis is on the rise, with associated under-nutrition, diabetes, increasing prevalence of immunosuppression associated with AIDS, immunosuppressant drugs used with cancer chemotherapy or transplants, etc. Variable degree of drug resistance, non-compliance to treatment due to the long duration and various complications of the therapy has further added to the predicament [1][2][3][4]. All this has created a large group of patients who suffer from the various sequelae of pulmonary tuberculosis due to involvement of the airway, parenchyma, pleura, or pulmonary vasculature [5,6].…”

Latent Mycobacterium tuberculosis infection provides protection for the host by changing the activation state of the innate immune system

“…The failure to identify mechanisms or correlates of protection against TB has hampered the development of vaccines or host-directed therapies to combat the world-wide disease burden which is estimated to be 10.4 million cases and 1.8 million deaths annually 5 . The immune mechanisms that protect against TB are evidently quite powerful: Due to the extraordinarily high prevalence of Mycobacterium tuberculosis (Mtb) (some estimates suggest that at least 25% of the world's population has been exposed 2 ) TB ranks as the deadliest infectious disease world-wide.…”

Susceptibility and Sustainability of India against CoVid19: a multivariate approach

“…This observation has a significant impact in our final outcome. This data is collected from WHO and review articles [18][19][20]. The additional factors included in this study are the impact of lung cancer (LC), chronic obstructive pulmonary disease (COPD) and Lower respiratory infect (LRI).…”